Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX)’s Stock Is Sell After More Market Selling

December 8, 2017 - By Adrian Erickson

 Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX)'s Stock Is Sell After More Market Selling

Investors sentiment increased to 1.68 in Q2 2017. Its up 0.18, from 1.5 in 2017Q1. It increased, as 15 investors sold BioCryst Pharmaceuticals, Inc. shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 66.24 million shares or 8.58% more from 61.01 million shares in 2017Q1 were reported.
Moreover, California State Teachers Retirement has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 141,883 shares. State Board Of Administration Of Florida Retirement owns 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 54,434 shares. Tiaa Cref Inv Mngmt Ltd Com holds 0% or 468,882 shares in its portfolio. Schwab Charles Invest Management has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). State Street stated it has 3.91 million shares or 0% of all its holdings. Dafna Cap Management Limited Com holds 591,128 shares. Aqr Management Lc has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Acuta Prns Limited Liability Co holds 168,685 shares. Blackrock invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Goldman Sachs Group Inc owns 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 924,757 shares. Fmr Ltd Limited Liability Company has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Meeder Asset Mgmt Incorporated holds 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) or 156 shares. Moreover, Janney Montgomery Scott Lc has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Commonwealth Equity Serv reported 40,755 shares or 0% of all its holdings. Invesco Limited stated it has 956,224 shares.

The stock of Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) registered an increase of 3.81% in short interest. BCRX’s total short interest was 11.09 million shares in December as published by FINRA. Its up 3.81% from 10.69M shares, reported previously. With 1.09M shares average volume, it will take short sellers 10 days to cover their BCRX’s short positions. The short interest to Biocryst Pharmaceuticals Incorporated’s float is 21.19%.

The stock decreased 0.44% or $0.02 during the last trading session, reaching $4.57. About 663,349 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since December 8, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $449.71 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 13 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. BioCryst Pharmaceuticals has $16 highest and $2 lowest target. $7.33’s average target is 60.39% above currents $4.57 stock price. BioCryst Pharmaceuticals had 31 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Overweight” rating by PiperJaffray on Friday, August 12. The rating was downgraded by Needham on Tuesday, February 9 to “Hold”. The rating was maintained by Jefferies on Friday, August 5 with “Hold”. The rating was downgraded by JP Morgan on Tuesday, February 9 to “Neutral”. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Outperform” rating by FBR Capital on Tuesday, February 9. The firm has “Buy” rating given on Tuesday, August 8 by H.C. Wainwright. Ladenburg Thalmann initiated the stock with “Buy” rating in Thursday, February 16 report. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by JMP Securities on Tuesday, November 28. The stock has “Buy” rating by Noble Financial on Tuesday, August 8. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Buy” rating given on Wednesday, September 6 by Jefferies.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by: Prnewswire.com, which released: “Biotech Stock Performance Review — BioCryst Pharma, Celgene, Exelixis, and Geron” on November 21, 2017. Seekingalpha.com‘s article titled: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results …” and published on November 07, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: